Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADCElerate1: ADCE-D01 in Advanced Soft Tissue Sarcoma
NCT06797999Phase 2Recruiting
- Sponsor
- Adcendo
- Start
- Jun 2025
- Primary completion
- Feb 2029
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of ADCE-D01 in soft tissue sarcoma (STS), sponsored by Adcendo. Primary endpoints: Maximum Tolerated Dose and Recommended Phase 2 Dose at 18 months and Safety and Tolerability evaluated by incidence of DLTs at 18 months. Started Jun 2025; status: recruiting.
02
Drugs
ADCE-D01
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06797999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06797999.